ES2099211T3 - Conjugados citomoduladores de miembros de parejas de union especifica. - Google Patents

Conjugados citomoduladores de miembros de parejas de union especifica.

Info

Publication number
ES2099211T3
ES2099211T3 ES92303618T ES92303618T ES2099211T3 ES 2099211 T3 ES2099211 T3 ES 2099211T3 ES 92303618 T ES92303618 T ES 92303618T ES 92303618 T ES92303618 T ES 92303618T ES 2099211 T3 ES2099211 T3 ES 2099211T3
Authority
ES
Spain
Prior art keywords
conjugates
cytomodulating
couples
members
specific union
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92303618T
Other languages
English (en)
Other versions
ES2099211T5 (es
Inventor
Philippe Pouletty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangstat Medical Corp
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24772845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2099211(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of ES2099211T3 publication Critical patent/ES2099211T3/es
Application granted granted Critical
Publication of ES2099211T5 publication Critical patent/ES2099211T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTAN NUEVOS CONJUGADOS QUE CONTIENE UNA UNIDAD CAPAZ DE ENLAZARSE ESPECIFICAMENTE A UNA CELULA OBJETIVO UNIDA A UNA UNIDAD SELECTIVA PARA ENLAZARSE A UN AGENTE PROVOCADOR DE EFECTOS ENDOGENO, CAPAZ DE CAUSAR LA INACTIVACION DE LA CELULA O CITOTOXICIDAD. EJEMPLOS DE CONJUGADOS SON UN LIGANDO PARA UNA PROTEINA DE MEMBRANA SUPERFICIAL, EJ. UN RECEPTOR DE IL-2, UNIDO A UN ANTIGENO A O B POLISACARIDO. LOS CONJUGADOS SE PUEDEN UTILIZAR ESPECIFICAMENTE PARA DESTRUIR LAS CELULAS ASOCIADAS A UNA CONDICION PATOGENICA.
ES92303618T 1991-04-23 1992-04-22 Conjugados citomoduladores de miembros de parejas de union especifica. Expired - Lifetime ES2099211T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69053091A 1991-04-23 1991-04-23
US690530 1991-04-23

Publications (2)

Publication Number Publication Date
ES2099211T3 true ES2099211T3 (es) 1997-05-16
ES2099211T5 ES2099211T5 (es) 2004-02-01

Family

ID=24772845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92303618T Expired - Lifetime ES2099211T5 (es) 1991-04-23 1992-04-22 Conjugados citomoduladores de miembros de parejas de union especifica.

Country Status (7)

Country Link
EP (1) EP0510949B2 (es)
JP (1) JP3105629B2 (es)
AT (1) ATE147993T1 (es)
CA (1) CA2066810A1 (es)
DE (1) DE69216899T3 (es)
DK (1) DK0510949T3 (es)
ES (1) ES2099211T5 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
ES2543819T3 (es) * 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
ES2333845T3 (es) 1999-01-06 2010-03-02 University Of Southern California Metodo y composicion para la inhibicion de la angiogenesis.
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
CA2379373A1 (en) 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CN1441676B (zh) 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
EP2230249A3 (en) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
CA2734173C (en) * 2007-10-18 2019-04-23 Mayo Foundation For Medical Education And Research Igm-mediated receptor clustering
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
EP3600283A4 (en) 2017-03-27 2020-12-16 Immunomedics, Inc. TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE74622T1 (de) † 1984-10-31 1992-04-15 Massachusetts Inst Technology Verfahren zum sensibilisieren einer zielzelle zum lysen durch cytotoxische t-lymphkoerperchen.
GB8626413D0 (en) † 1986-11-05 1986-12-03 Gilliland L K Antibodies
DE3880766D1 (de) * 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
EP0334300A1 (en) † 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
DE3825615A1 (de) † 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
GB8907310D0 (en) † 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
EP0547163B1 (en) * 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core

Also Published As

Publication number Publication date
JPH07173071A (ja) 1995-07-11
DE69216899T2 (de) 1997-06-12
DE69216899T3 (de) 2004-01-15
EP0510949A3 (en) 1992-12-09
ES2099211T5 (es) 2004-02-01
CA2066810A1 (en) 1992-10-24
JP3105629B2 (ja) 2000-11-06
EP0510949A2 (en) 1992-10-28
DK0510949T3 (da) 1997-07-28
DE69216899D1 (de) 1997-03-06
ATE147993T1 (de) 1997-02-15
EP0510949B2 (en) 2003-04-02
EP0510949B1 (en) 1997-01-22

Similar Documents

Publication Publication Date Title
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ECSP941122A (es) Derivados de 5-arilindoles
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2168785T3 (es) Absorcion de minerales por las celulas intestinales.
IT7823672A0 (it) Derivati di idantoina ad azione terapeutica e relativo procedimento di preparazione.
ES2170771T3 (es) Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.
ES2149768T3 (es) Conjugados de agentes enlazantes de celulas derivados de cc-1065.
ES2103966T3 (es) Uso de una timosina en el tratamiento de hepatitis c.
ES2010226A6 (es) Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos
ES279281U (es) Dispositivo de apoyo para una persona
ES2074268T3 (es) Vacunacion idiotipica contra el linfoma de celulas b.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
ES2193192T3 (es) Receptores de interleuquina-15.
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
ES2135316B1 (es) Guia por barra y procedimiento para su fabricacion.
IT8821271A0 (it) Derivati benzimidazolici farmacologicamente attivi.
ES2166900T3 (es) Derivados de ara-c.
SE7803646L (sv) Salva for huddesinfektion och sett att framstella densamma
ATE6358T1 (de) 2-aminotetralin-verbindungen und pharmazeutische zusammensetzungen mit zentraler alpha1-agonist- wirksamkeit.
AR246310A1 (es) Procedimiento para la preparacion de la cadena alfa- del receptor de la interleucina 5 humana, o partes del mismo, secuencia del adn, vector y celula hospedante.
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2063412T3 (es) Tableta y granulado que contienen como principio activo mesna.
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 510949

Country of ref document: ES